Metotab (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, lowering tetrahydrofolate levels needed for DNA, RNA and protein synthesis. This limits the proliferation of immune cells involved in inflammation and of malignant cells, providing both immunosuppressive and cytotoxic effects.

The appropriate dose of Metotab is individualized by the prescribing clinician based on the specific indication, disease severity, patient weight, renal and hepatic function, and response to therapy. No fixed regimen is provided here; dosing decisions are made by a qualified healthcare professional.

Methotrexate is classified as pregnancy category X because it is known to cause fetal malformations and embryotoxicity. It is contraindicated in pregnancy and should be stopped well before conception. Breastfeeding is also discouraged, as the drug can be excreted in milk and affect the infant.

To request Metotab, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with biologic DMARDs such as TNF‑α inhibitors, methotrexate is an oral, small‑molecule agent that is less costly and does not require injection. However, biologics may offer faster symptom control in some patients. Methotrexate also differs from other antimetabolites like azathioprine by targeting folate metabolism rather than purine synthesis.

Metotab tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Metotab is taken orally as a tablet. Patients should swallow the tablet whole with a full glass of water, with or without food, as directed by their prescriber. Dosing frequency and any dose adjustments are determined by the treating physician.

The most critical adverse effects include severe liver toxicity (hepatitis, fibrosis), pulmonary fibrosis or interstitial lung disease, and profound bone‑marrow suppression leading to pancytopenia. Patients should report persistent abdominal pain, unexplained bruising, shortness of breath, or yellowing of the skin promptly.

Metotab should be avoided in pregnant or nursing women, individuals with known hypersensitivity to methotrexate, and patients with severe hepatic or renal impairment. Caution is also advised for those with active infections, uncontrolled diabetes, or a history of pulmonary disease.